Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CD38 inhibitor
DRUG CLASS:
CD38 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
daratumumab (26)
isatuximab-irfc (11)
daratumumab/hyaluronidase (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
daratumumab (26)
isatuximab-irfc (11)
daratumumab/hyaluronidase (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
SG301 IV (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
›
Associations
(51)
News
Trials
Search handles
@Abdallah81MD
@CyclingDoctor
@DrGarethMorgan1
@DrOlaLandgren
@EhsanMalekMD
@Myeloma_Doc
@PLMcCarthyMD
@Rfonsi1
@VincentRK
@akeithstewart
@mtmdphd
Search handles
@Abdallah81MD
@CyclingDoctor
@DrGarethMorgan1
@DrOlaLandgren
@EhsanMalekMD
@Myeloma_Doc
@PLMcCarthyMD
@Rfonsi1
@VincentRK
@akeithstewart
@mtmdphd
Filter by
Latest
8ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
8 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
8ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
8 months ago
lenalidomide • Darzalex (daratumumab)
9ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
9 months ago
lenalidomide • Darzalex (daratumumab)
9ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
9 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
9ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
9 months ago
lenalidomide • Darzalex (daratumumab)
9ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
9 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
9ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
9 months ago
lenalidomide • Darzalex (daratumumab)
9ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
9 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
9ms
Initial myeloma therapy is a great example, DarzalexRVD is such a complex regimen to explain at first, we all use these conversation devices to convince ourselves we did a good job but the nurses later will say: “they have no idea what you said, all they heard was cancer” (@shycollie)
9 months ago
Darzalex (daratumumab)
9ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
9 months ago
lenalidomide • Darzalex (daratumumab)
9ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
9 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
Amazing times @mayoclinic #myeloma team circa 2010 global team, fellows from argentina, netherlands, montreal, edmonton, mexico, wurzburg did 1st whole genomes, 1st myeloma gene panel, 1st in man carfilzomib, isatuximab, new mouse models, cereblon etc. Many babies arrived! (@akeithstewart)
10 months ago
CRBN (Cereblon)
|
carfilzomib • Sarclisa (isatuximab-irfc)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUkfVv Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOeiugZ #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
Predictive Markers of High-Grade or Serious Tx-Emergent Infections w/ Daratumumab-Based Regimens in NDMM - Van De Donk et al. #ASH20 Abs 3209 https://t.co/E2Jv6CixC7 #mmsm #IDonc The final (MVA) predictive model included age, LDH, albumin & elevated baseline ALT levels (Table) (@mtmdphd)
10 months ago
Darzalex (daratumumab)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
Kashyap Padmaraju presents cool data on achieving better quality of care for #MultipleMyeloma patients with subcutaneous #Daratumumab treatment without any premedication. @bdermanmd @UChicagoHemOnc @UCCancerCenter @UChicagoMed (@UCCancerCenter)
10 months ago
Clinical
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
#ASCO23 @DholariaMD et al presents phase 2 trial results for Talquetamab + daratumumab in patients with relapsed/refractory multiple #myeloma: Updated TRIMM-2 results @BldCancerDoc (@OncLive)
10 months ago
Clinical • P2 data
|
Darzalex (daratumumab) • Talvey (talquetamab-tgvs)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
Analysis of data among Black participants treated with a daratumumab-containing D-RVd regimen from the #GRIFFINStudy in #MultipleMyeloma by @AjayNookaMD and colleagues https://t.co/2GZhxEG57D (@Plainlang_FSG)
10 months ago
Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
Highlighting Progress in Myeloma Treatment: POLLUX Trial Final Overall Survival Results With Daratumumab-Based Therapy, by Shaji Kumar, MD https://t.co/hrloOxuPnO #mmsm #MultipleMyeloma #hematology @myelomaMD (@ASCOPost)
10 months ago
Clinical
|
Darzalex (daratumumab)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
📣Our latest @TheIACH Journal Club: Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) Now available on-demand! 📽️View the full webinar for FREE https://t.co/rI1oBq60nF @thanosdimop @Mohty_EBMT (@TheIACH)
10 months ago
Clinical
|
lenalidomide • Darzalex (daratumumab)
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
10ms
📣Join us NOW! ⬇️⬇️⬇️ https://t.co/y9wgvPS088 Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) ✍️FREE registration! @thanosdimop @Mohty_EBMT (@TheIACH)
10 months ago
Clinical
|
lenalidomide • Darzalex (daratumumab) • dexamethasone
10ms
📣Join us TOMORROW for @TheIACH Journal Club: Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) FREE registration⬇️ https://t.co/7tD8XQnQ2F Tuesday, May 23 2023 6pm Paris, 12pm NY @thanosdimop @Mohty_EBMT (@TheIACH)
10 months ago
Clinical
|
lenalidomide • Darzalex (daratumumab) • dexamethasone
10ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
10 months ago
lenalidomide • Darzalex (daratumumab)
10ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
10 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm (@mtmdphd)
11 months ago
Clinical • Minimal residual disease
|
Darzalex Faspro (daratumumab/hyaluronidase)
11ms
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd (@mtmdphd)
11 months ago
lenalidomide • Darzalex (daratumumab)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login